Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Marchand

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|May 14, 2009
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cellsViolaine François, Sabrina Ottaviani, Nicolina Renkvist, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2004
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumorsValérie Vantomme, Christine Dantinne, Noreddine Amrani, et al.
Immunological Reviews|November 26, 2002
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigenPierre G Coulie, Vaios Karanikas, Christophe Lurquin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 proteinYi Zhang, Zhaojun Sun, Hugues Nicolay, et al.
The American Journal of Medicine|October 18, 2003
Comparison of four clinical prediction scores for the diagnosis of lower limb deep venous thrombosis in outpatientsJoël Constans, Catherine Boutinet, L Rachid Salmi, et al.
Cancer Immunity|May 20, 2004
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFADanielle Liénard, Donata Rimoldi, Marie Marchand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2005
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cellsNicolas van Baren, Marie-Claude Bonnet, Brigitte Dréno, et al.
International Journal of Cancer|June 10, 2005
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanomaWim H J Kruit, Heidi H van Ojik, Vincent G Brichard, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|May 14, 2009
The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cellsViolaine François, Sabrina Ottaviani, Nicolina Renkvist, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 11, 2004
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumorsValérie Vantomme, Christine Dantinne, Noreddine Amrani, et al.
Immunological Reviews|November 26, 2002
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigenPierre G Coulie, Vaios Karanikas, Christophe Lurquin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 proteinYi Zhang, Zhaojun Sun, Hugues Nicolay, et al.
The American Journal of Medicine|October 18, 2003
Comparison of four clinical prediction scores for the diagnosis of lower limb deep venous thrombosis in outpatientsJoël Constans, Catherine Boutinet, L Rachid Salmi, et al.
Cancer Immunity|May 20, 2004
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFADanielle Liénard, Donata Rimoldi, Marie Marchand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2005
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cellsNicolas van Baren, Marie-Claude Bonnet, Brigitte Dréno, et al.
International Journal of Cancer|June 10, 2005
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanomaWim H J Kruit, Heidi H van Ojik, Vincent G Brichard, et al.
Pageof 2